Published online May 21, 2016. doi: 10.3748/wjg.v22.i19.4716
Peer-review started: February 13, 2016
First decision: March 7, 2016
Revised: March 10, 2016
Accepted: March 30, 2016
Article in press: March 30, 2016
Published online: May 21, 2016
Processing time: 95 Days and 22.2 Hours
AIM: To investigate the expression pattern of plasma long noncoding RNAs (lncRNAs) in Chrohn’s disease (CD) patients.
METHODS: Microarray screening and qRT-PCR verification of lncRNAs and mRNAs were performed in CD and control subjects, followed by hierarchy clustering, GO and KEGG pathway analyses. Significantly dysregulated lncRNAs were categorized into subgroups of antisense lncRNAs, enhancer lncRNAs and lincRNAs. To predict the regulatory effect of lncRNAs on mRNAs, a CNC network analysis was performed and cross linked with significantly changed lncRNAs. The overlapping lncRNAs were randomly selected and verified by qRT-PCR in a larger cohort.
RESULTS: Initially, there were 1211 up-regulated and 777 down-regulated lncRNAs as well as 1020 up-regulated and 953 down-regulated mRNAs after microarray analysis; a heat map based on these results showed good categorization into the CD and control groups. GUSBP2 and AF113016 had the highest fold change of the up- and down-regulated lncRNAs, whereas TBC1D17 and CCL3L3 had the highest fold change of the up- and down-regulated mRNAs. Six (SNX1, CYFIP2, CD6, CMTM8, STAT4 and IGFBP7) of 10 mRNAs and 8 (NR_033913, NR_038218, NR_036512, NR_049759, NR_033951, NR_045408, NR_038377 and NR_039976) of 14 lncRNAs showed the same change trends on the microarray and qRT-PCR results with statistical significance. Based on the qRT-PCR verified mRNAs, 1358 potential lncRNAs with 2697 positive correlations and 2287 negative correlations were predicted by the CNC network.
CONCLUSION: The plasma lncRNAs profiles provide preliminary data for the non-invasive diagnosis of CD and a resource for further specific lncRNA-mRNA pathway exploration.
Core tip: The pathogenesis of Chrohn’s disease (CD) is unclear while increasing evidence supports the involvement of epigenomic regulation. In this study, we jointly used microarray screening and qRT-PCR verification to achieve the plasma specific long noncoding RNAs expression profile of patients with CD and their potential regulation of downstream mRNAs. Our results would provide preliminary data for non-invasive diagnosis of CD and a reservoir for specific lncRNA-mRNA pathway exploration in the future.